ARAV - Cantor cuts Aravive to neutral as biotech struggles to stay in business
2023-08-22 16:09:27 ET
- Aravive sinks amid downgrades after Phase 3 setback for lead asset
- Aravive stock pops on FDA orphan drug status for batiraxcept to treat pancreatic cancer
- Aravive gains on FDA Fast Track status for lead program
- Aravive to raise $41.5M in direct stock offering
- Seeking Alpha’s Quant Rating on Aravive
- Earnings data for Aravive
For further details see:
Cantor cuts Aravive to neutral as biotech struggles to stay in business